-+ 0.00%
-+ 0.00%
-+ 0.00%

MBX Biosciences plans Q3 2026 Phase 3 trial for once-weekly canvuparatide in hypoparathyroidism

Reuters·03/09/2026 12:04:04

Please log in to view news